Elucid, a Boston-based healthcare technology company focused on using artificial intelligence (AI) to treat cardiovascular disease (CVD), has announced that Scott Huennekens is the new executive chairman of its board of directors.
Huennekens has more than 25 years of experience in the medical device space. He served as the president and CEO of Volcano Corporation before it was acquired by Philips in 2015, for example, and he also previously held those two positions with Verb Surgical and Digirad Corp.
“It is an honor to join Elucid as chairman of the board of directors,” Huennekens said in a prepared statement. “Elucid technology is a powerful and proven tool designed to advance coronary artery disease risk prediction and management in the cardiology practice. Characterizing risk of heart attack and stroke is an unmet need, and Elucid technology has the potential to change the way we diagnose patients at risk to provide a new standard of care.”
“There are few medtech leaders with Scott’s vast experience and his particular expertise in technology characterizing vascular disease is perfectly aligned to Elucid’s mission,” added Elucid CEO Blake Richards. “He has a proven track record in building innovative companies addressing large, unmet clinical needs. Having Scott join us as executive chairman at this phase in the company’s rapid growth will be invaluable towards achieving our mission of unprecedented precision healthcare to reduce deaths from heart attack and stroke.”
This is the second significant addition Elucid has made to its board of directors in recent months. Back in November 2022, the company added cardiologist and industry CEO Michael D. Lesh, MD, to the board, praising his “proven track record” in the treatment of CVD.
Michael has more than 16 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.